Combination gerotherapeutic interventions for healthspan improvement
exploratorydrug program · high · Wed Jul 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Explore whether multi-modal gerotherapy combinations improve longevity-related outcomes.
90-day interventional, randomized, controlled pilot trial with up to 30 subjects assigned to control, multi-therapy with B12, naltrexone, metformin, and NAD+, or comprehensive therapy with rapamycin, naltrexone, metformin, B12, NAD+, GSH, and Infinite Supplement.
ClinicalTrials.gov record published July 23, 2025.
PEARL low-dose rapamycin healthspan trial
exploratorydrug program · high · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate long-term safety and effects of intermittent low-dose rapamycin on healthspan metrics in healthy normative-aging adults.
48-week decentralized, double-blinded, randomized, placebo-controlled trial of weekly compounded rapamycin at 5 mg or 10 mg versus placebo, with DXA, blood biomarkers, adverse-event monitoring, and health/well-being surveys.
Peer-reviewed 2025 Aging publication of PEARL trial results after earlier 2024 medRxiv preprint.
Adverse and serious adverse events were similar across groups. Visceral adiposity did not significantly change. Blood biomarker changes stayed within normal ranges. Women receiving 10 mg rapamycin had significant improvements in lean tissue mass and self-reported pain; 5 mg users had improvements in emotional well-being and general health.
Rapamycin bioavailability and blood-level monitoring program
exploratoryresearch program · high · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Characterize blood levels, formulation differences, dose-to-blood-level relationships, and monitoring needs for low-dose rapamycin used for longevity.
Real-world cohort analysis comparing commercial/generic and compounded rapamycin blood levels after self-administration, including AgelessRx Observational Research Database users and clinical-trial registry study NCT06550271.
2025 GeroScience publication reporting real-world cohort findings and recommending individualized dosing with routine blood rapamycin monitoring.
Dose-to-blood-level relationships were approximately linear. Compounded rapamycin showed lower bioavailability per milligram than commercial/generic formulations. Blood levels showed substantial inter-individual heterogeneity but relative within-person consistency over time; levels peaked around 2 days with gradual decline thereafter in the observational database cohort.
Rapamycin plus low-dose naltrexone bone-density case evidence
exploratoryresearch program · medium · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Document potential bone-density effects associated with low-dose rapamycin and low-dose naltrexone use in an aging-related osteopenia context.
Case report of a 52-year-old woman with osteopenia who participated in a low-dose rapamycin clinical trial and subsequently used low-dose naltrexone.
2025 Cureus case report publication.
The case report described an unexpected 15.9% increase in lumbar spine bone mineral density within two years.
Alternative therapies for maintaining weight loss after GLP-1 cessation
exploratorydrug program · high · Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate whether metformin alone or in combination with rapamycin or low-dose naltrexone helps maintain weight loss after patients discontinue GLP-1 receptor agonist therapy.
Randomized controlled trial comparing control, metformin, metformin plus rapamycin, and metformin plus low-dose naltrexone over six months post-cessation, with weight regain, metabolic biomarkers, quality-of-life outcomes, blood work, and wearable data.
ClinicalTrials.gov record published December 17, 2024.
Microdosed GLP-1 health, quality-of-life, and longevity study
exploratorydrug program · high · Fri Nov 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess whether microdosed GLP-1 receptor agonists improve health, quality of life, longevity measures, weight management, and metabolic health.
Clinical study of microdosed GLP-1 receptor agonist therapy measuring health, quality-of-life, longevity, weight-management, and metabolic outcomes.
ClinicalTrials.gov record published November 1, 2024.
Canagliflozin pulsatile dosing in healthy individuals
exploratorydrug program · high · Mon Feb 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Measure whether canagliflozin reduces average glucose in healthy individuals and assess tolerability, side effects, and urinary glucose excretion under a pulsatile dosing protocol.
Clinical trial of canagliflozin intervention in healthy individuals with glucose, tolerability, side-effect, and urinary glucose-excretion endpoints.
ClinicalTrials.gov record published February 12, 2024.
Acarbose safety and glucose-spike reduction in healthy individuals
exploratorydrug program · high · Wed Aug 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess safety and efficacy of acarbose for reducing glucose spikes after carbohydrate consumption in healthy individuals.
Prospective clinical trial of acarbose in healthy individuals measuring glucose-spike reduction after carbohydrate consumption.
ClinicalTrials.gov record published August 10, 2022.
AgelessRx longevity telehealth treatment platform
undisclosedplatform · medium
Provide online access to longevity-focused diagnostics, therapeutics, and medical protocols reviewed by US-licensed medical providers.
Online assessments, clinician review, diagnostics, and access to products including NAD+, GSH, low-dose naltrexone, metformin, and biological-age tests.
Company site states AgelessRx provides online longevity treatments and advanced as one of 40 global semifinalist teams in the XPRIZE Healthspan competition.
Low-dose naltrexone diseases-of-aging observational study
exploratorydrug program · medium
Assess health status in short- and long-term low-dose naltrexone users, with relevance to diseases of aging.
Retrospective observational study of low-dose naltrexone users.
Clinical-trial public record identified in supplied material.
